As new medications enter the market, we’ve observed a troubling new trend: an influx of clinically superfluous brand drugs that carry hefty price tags but offer little to no added clinical value.
Recently, manufacturers have launched new brand-name prescription wound dressings that include similar combinations of ingredients as OTC and lower-cost generic products yet are priced far higher than the alternatives — up to 125 times more.
This report shines a spotlight on the latest category: Wound care.
Related healthcare insights
Video
Hear how the industry’s most transparent and independent Pharmacy & Therapeutics Committee evaluates drugs for the Optum Rx formulary.
Article
Learn more about why evidence-based criteria and clinician insight are needed for informed and trustworthy decisions while leveraging AI.
Article
Michael Einodshofer addresses the risks, challenges and opportunities facing the industry.